Technical Analysis for IMRX - Immuneering Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Earnings Movers | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Earnings Movers | Other | 4.49% | |
Wide Bands | Range Expansion | 4.49% | |
20 DMA Resistance | Bearish | -1.21% | |
Doji - Bearish? | Reversal | -1.21% | |
Outside Day | Range Expansion | -1.21% | |
Wide Bands | Range Expansion | -1.21% | |
Up 3 Days in a Row | Strength | -1.21% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 11 hours ago |
20 DMA Resistance | about 11 hours ago |
Up 10% | about 11 hours ago |
60 Minute Opening Range Breakout | about 12 hours ago |
Up 5% | about 12 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/07/2024
Immuneering Corporation Description
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Solid Tumors Oncology Neuroscience Drug Development Signal Transduction Advanced Solid Tumors Bioinformatics mTOR
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.92 |
52 Week Low | 1.38 |
Average Volume | 942,745 |
200-Day Moving Average | 6.22 |
50-Day Moving Average | 2.97 |
20-Day Moving Average | 1.68 |
10-Day Moving Average | 1.54 |
Average True Range | 0.22 |
RSI (14) | 35.48 |
ADX | 44.98 |
+DI | 14.93 |
-DI | 29.53 |
Chandelier Exit (Long, 3 ATRs) | 1.55 |
Chandelier Exit (Short, 3 ATRs) | 2.05 |
Upper Bollinger Bands | 2.07 |
Lower Bollinger Band | 1.28 |
Percent B (%b) | 0.44 |
BandWidth | 47.01 |
MACD Line | -0.36 |
MACD Signal Line | -0.46 |
MACD Histogram | 0.106 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.92 | ||||
Resistance 3 (R3) | 1.91 | 1.82 | 1.87 | ||
Resistance 2 (R2) | 1.82 | 1.74 | 1.82 | 1.85 | |
Resistance 1 (R1) | 1.72 | 1.70 | 1.77 | 1.73 | 1.84 |
Pivot Point | 1.63 | 1.63 | 1.65 | 1.63 | 1.63 |
Support 1 (S1) | 1.53 | 1.55 | 1.58 | 1.54 | 1.42 |
Support 2 (S2) | 1.44 | 1.51 | 1.44 | 1.41 | |
Support 3 (S3) | 1.34 | 1.44 | 1.39 | ||
Support 4 (S4) | 1.35 |